Regenicin, Inc. (RGIN) financial statements (2021 and earlier)
Company profile
| Business Address |
10 HIGH COURT LITTLE FALLS, NJ 07424 |
| State of Incorp. | NV |
| Fiscal Year End | September 30 |
| SIC | 3841 - Surgical and Medical Instruments and Apparatus (benchmarking) |
| More info | Complete financial analysis Financial benchmarking |
Balance sheet (Statement of financial position) ($ in thousands)
| 12/31/2019 TTM | 9/30/2019 | 9/30/2018 | 9/30/2017 | 9/30/2016 | 9/30/2015 | |||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash, cash equivalents, and short-term investments | 2 | 1 | 3 | 19 | 219 | 1,061 | ||
| Cash and cash equivalents | 2 | 1 | 3 | 19 | 219 | 1,061 | ||
| Other undisclosed current assets | 69 | 74 | 419 | |||||
| Total current assets: | 2 | 1 | 3 | 88 | 293 | 1,481 | ||
| Noncurrent Assets | ||||||||
| Long-term investments and receivables | 67 | |||||||
| Due from related parties | 67 | |||||||
| Total noncurrent assets: | 67 | |||||||
| Other undisclosed assets | 3 | 5 | 54 | |||||
| TOTAL ASSETS: | 6 | 5 | 56 | 88 | 360 | 1,481 | ||
| LIABILITIES AND EQUITY | ||||||||
| Liabilities | ||||||||
| Current Liabilities | ||||||||
| Accounts payable and accrued liabilities | 3,079 | 3,278 | 2,696 | 2,286 | 1,399 | 682 | ||
| Accounts payable | 65 | 138 | 68 | 281 | 263 | 360 | ||
| Accrued liabilities | 144 | 231 | 206 | |||||
| Employee-related liabilities | 3,014 | 2,869 | 2,288 | 1,707 | 1,136 | |||
| Interest and dividends payable | 127 | 110 | 92 | 322 | ||||
| Debt | 10 | 10 | 10 | 10 | 10 | 10 | ||
| Other undisclosed current liabilities | 842 | 445 | 350 | 233 | 419 | 1,556 | ||
| Total current liabilities: | 3,931 | 3,733 | 3,056 | 2,529 | 1,828 | 2,249 | ||
| Noncurrent Liabilities | ||||||||
| Total liabilities: | 3,931 | 3,733 | 3,056 | 2,529 | 1,828 | 2,249 | ||
| Stockholders' equity | ||||||||
| Stockholders' equity attributable to parent, including: | (3,926) | (3,728) | (3,000) | (2,441) | (1,468) | (768) | ||
| Common stock | 158 | 158 | 158 | 158 | 158 | 158 | ||
| Additional paid in capital | 10,208 | 10,208 | 10,178 | 10,178 | 10,178 | 9,788 | ||
| Accumulated other comprehensive income | 1 | 1 | ||||||
| Accumulated deficit | (14,288) | (14,090) | (13,333) | (12,774) | (11,800) | (10,710) | ||
| Other undisclosed stockholders' equity attributable to parent | (4) | (4) | (4) | (4) | (4) | (4) | ||
| Total stockholders' equity: | (3,926) | (3,728) | (3,000) | (2,441) | (1,468) | (768) | ||
| TOTAL LIABILITIES AND EQUITY: | 6 | 5 | 56 | 88 | 360 | 1,481 | ||
Income statement (P&L) ($ in thousands)
| 12/31/2019 TTM | 9/30/2019 | 9/30/2018 | 9/30/2017 | 9/30/2016 | 9/30/2015 | ||
|---|---|---|---|---|---|---|---|
| Gross profit: | 249 | 15 | 416 | ||||
| Operating expenses | (690) | (737) | (789) | (976) | (1,196) | (242) | |
| Other operating income (expense), net (Other Expenses) | (14) | (22) | (19) | 13 | 310 | (3,313) | |
| Other undisclosed operating income (loss) | 14 | 22 | 19 | (13) | (310) | 3,313 | |
| Operating loss: | (690) | (737) | (540) | (961) | (780) | (242) | |
| Nonoperating income (expense) (Investment Income, Nonoperating) | (0) | (2,993) | (293) | 2,700 | |||
| Interest and debt expense | (18) | (18) | 230 | 32 | 434 | 1,036 | |
| Other undisclosed income from continuing operations before equity method investments, income taxes | 4 | ||||||
| Income (loss) from continuing operations before equity method investments, income taxes: | (704) | (755) | (310) | (3,921) | (639) | 3,494 | |
| Other undisclosed loss from continuing operations before income taxes | (451) | (423) | |||||
| Income (loss) from continuing operations before income taxes: | (704) | (755) | (310) | (3,921) | (1,090) | 3,072 | |
| Income tax expense | (2,829) | (2,829) | |||||
| Net income (loss): | (704) | (755) | (310) | (3,921) | (3,919) | 243 | |
| Other undisclosed net income (loss) attributable to parent | 1,047 | 1,513 | (249) | 4,895 | 2,829 | ||
| Net income (loss) attributable to parent: | 343 | 758 | (559) | 974 | (1,090) | 243 | |
| Other undisclosed net loss available to common stockholders, basic | (1,123) | (1,588) | |||||
| Net income (loss) available to common stockholders, basic: | (780) | (829) | (559) | 974 | (1,090) | 243 | |
| Dilutive securities, effect on basic earnings per share | 8,850 | ||||||
| Net income (loss) available to common stockholders, diluted: | (780) | (829) | (559) | 974 | (1,090) | 9,093 | |
Comprehensive Income ($ in thousands)
| 12/31/2019 TTM | 9/30/2019 | 9/30/2018 | 9/30/2017 | 9/30/2016 | 9/30/2015 | ||
|---|---|---|---|---|---|---|---|
| Net income (loss): | (704) | (755) | (310) | (3,921) | (3,919) | 243 | |
| Comprehensive income (loss): | (704) | (755) | (310) | (3,921) | (3,919) | 243 | |
| Other undisclosed comprehensive income (loss), net of tax, attributable to parent | (248) | 2,948 | |||||
| Comprehensive income (loss), net of tax, attributable to parent: | (704) | (755) | (559) | (973) | (3,919) | 243 | |
Statements sources
The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.